PHS
ASND icon

PFM Health Sciences’s Ascendis Pharma A/S ASND Stock Holding History

PFM Health Sciences’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.12M Buy
+22,400
New +$5.02M 0.47% 63

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PFM Health Sciences's ASND Position: Q1 2026 in Review

PFM Health Sciences reduced its Ascendis Pharma A/S (ASND) stake by 14% in Q1 2026, selling an estimated $5.75M and leaving 152,034 shares worth $34.8M. The position accounts for 3.17% of the portfolio, ranked #7.

PFM Health Sciences first reported a position in ASND in Q4 2018 and has held it in 9 quarters since. The position peaked at $38.3M in Q2 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • PFM Health Sciences held 152,034 shares of Ascendis Pharma A/S worth $34.8M as of Q1 2026.
  • PFM Health Sciences sold 25,651 Ascendis Pharma A/S shares in Q1 2026, an estimated $5.75M.
  • Ascendis Pharma A/S made up 3.17% of PFM Health Sciences's portfolio in Q1 2026, its #7 holding.
  • PFM Health Sciences first reported a position in Ascendis Pharma A/S in Q4 2018 and has held it in 9 quarters since.
  • PFM Health Sciences's Ascendis Pharma A/S position peaked at $38.3M in Q2 2025.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.